Sobi publishes Q4 and FY 2022 report: a good year and a solid future
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2022 Fourth quarter 2022 • Total revenue SEK 5,991 M (4,896), +22 per cent, +5 per cent at constant exchange rates (CER)i • Haematology revenue SEK 3,025 M (2,242), +19 per cent at CER of which Elocta® SEK 1,230 M (1,063), +6 per cent at CER; Alprolix® SEK 534 M (482), +1 per cent at CER; Doptelet® SEK 771 M (306), +107 per cent at CER and Aspaveli®/Empaveli® SEK 87 M (1) • Immunology revenue SEK 2,643 M (2,330), -6